Danesi R - Search Results

1

Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol.

Danesi R, Marchetti A, Bernardini N, La Rocca RV, Bevilacqua G, Del Tacca M. Danesi R, et al. Cancer Chemother Pharmacol. 1990;26(6):403-8. doi: 10.1007/BF02994089. Cancer Chemother Pharmacol. 1990. PMID: 2171795

2

[The physiopathological aspects of the atrial natriuretic factor].

Agen C, Bernardini N, Blandizzi C, Danesi R, Del Tacca M. Agen C, et al. Among authors: danesi r. Minerva Med. 1992 Apr;83(4):169-80. Minerva Med. 1992. PMID: 1315427 Review. Italian.

3

Characterization of the toxicity of distamycin derivatives on cancer cell lines and rat heart.

Agen C, Sironi AM, Danesi R, Costa M, Bernardini N, Paparelli A, Della Torre P, Del Tacca M. Agen C, et al. Among authors: danesi r. Toxicology. 1992 Nov 15;75(3):209-19. doi: 10.1016/0300-483x(92)90003-w. Toxicology. 1992. PMID: 1455430

4

Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4'-amino-3'-hydroxy-doxorubicin.

Danesi R, Bernardini N, Agen C, Costa M, Zaccaro L, Pieracci D, Malvaldi G, Del Tacca M. Danesi R, et al. Cancer Chemother Pharmacol. 1992;29(4):261-5. doi: 10.1007/BF00685942. Cancer Chemother Pharmacol. 1992. PMID: 1472260

5

Human skin disposition of cefpodoxime after oral administration of its proxetil ester.

Zolfino I, Senesi S, Campa M, Di Vito A, Mosca F, Favini P, Ducci M, Danesi R, Del Tacca M. Zolfino I, et al. Among authors: danesi r. J Antimicrob Chemother. 1992 Nov;30(5):731-3. doi: 10.1093/jac/30.5.731. J Antimicrob Chemother. 1992. PMID: 1493994 No abstract available.

6

Pattern of growth factor, proto-oncogene and carcinoembryonic antigen gene expression in human colorectal carcinoma cell lines.

La Rocca RV, Park JG, Danesi R, Del Tacca M, Steinberg SM, Gazdar AF. La Rocca RV, et al. Among authors: danesi r. Oncology. 1992;49(3):209-14. doi: 10.1159/000227040. Oncology. 1992. PMID: 1495747

7

The antiproliferative effect of suramin on the cancer cell line SW-13 is mediated by the inhibition of transforming growth factor beta 1 (TGF-beta 1).

Danesi R, Agen C, Bernardini N, Costa M, Del Tacca M. Danesi R, et al. Pharmacol Res. 1992 Feb-Mar;25 Suppl 1:17-8. doi: 10.1016/1043-6618(92)90519-h. Pharmacol Res. 1992. PMID: 1508796 No abstract available.

8

Doxorubicin cardiotoxicity is associated with alterations of plasma levels of atrial natriuretic factor.

Bernardini N, Agen C, Favilla S, Danesi R, Del Tacca M. Bernardini N, et al. Among authors: danesi r. J Endocrinol Invest. 1992 Feb;15(2):79-84. doi: 10.1007/BF03348668. J Endocrinol Invest. 1992. PMID: 1533234

9

Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529.

Agen C, Bernardini N, Danesi R, Della Torre P, Costa M, Del Tacca M. Agen C, et al. Among authors: danesi r. Cancer Chemother Pharmacol. 1992;30(2):95-9. doi: 10.1007/BF00686399. Cancer Chemother Pharmacol. 1992. PMID: 1600601

10

Cardiotoxicity and cytotoxicity of the anthracycline analog 4'-deoxy-4'-iodo-doxorubicin.

Danesi R, Bernardini N, Agen C, Costa M, Macchiarini P, Della Torre P, Del Tacca M. Danesi R, et al. Toxicology. 1991;70(2):243-53. doi: 10.1016/0300-483x(91)90050-b. Toxicology. 1991. PMID: 1763418

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

526 results

Search Page

Filters